Ole Morten Rønning
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ole Morten Rønning has a total of 415 co-authors. Here are the top co-authors by number of shared publications:
Bente Thommessen
Department of Neurology, Akershus University Hospital , PO Box 1000, 1478 Lørenskog
17 shared publications- Bente Thommessen
Department of Neurology, Akershus University Hospital, Lørenskog, Norway
6 shared publications - Håkon Ihle-Hansen
Department of Medicine, Bærum Hospital, Vestre Viken Hospital Trust
6 shared publications - Kashif Waqar Faiz
Department of Neurology Akershus University Hospital Lørenskog Norway
6 shared publications - Kristin Tveitan Larsen
Oslo University Hospital, Norway (H.E., K.T.L., E.F., Hege Ihle-Hansen, T.B.W., E.C.S.).
6 shared publications - Bjørn Guldvog
From the Foundation for Health Services Research, Central Hospital of Akershus, Nordbyhagen, Norway
5 shared publications
Latest Publications
- 18 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (8) , 2287-2294
Study of Antithrombotic Treatment After Intracerebral Hemorrhage-Antiplatelets: A Randomized Trial
BACKGROUND: Patients surviving spontaneous intracerebral hemorrhage (ICH) who have indications for antithrombotic treatment face increased risks of both hemorrhagic and ischemic events. The aim of STATICH (Study of Antithrombotic Treatment After Intracerebral Haemorrhage) was to assess the safety and efficacy of long-term antithrombotic treatment after ICH. METHODS: STATICH Antiplatelets (EudraCT 2014-002636-13; Unique identifier: NCT03186729) was a randomized, multicenter, open, blinded end point parallel-group trial, including adults with an indication for antiplatelet treatment to either start or avoid antiplatelet treatment. The target sample size was 500 participants. Patients were allocated 1:1 by a Web-based randomization system and followed for a minimum of 2 years. Outcome assessments were done by personnel blinded to treatment. Participants were not blinded. The primary safety outcome was recurrent symptomatic ICH. RESULTS: The trial was stopped early due to slow recruitment. Sixty-nine patients were included between August 2018 and December 2022: 34 were randomized to start antiplatelet treatment, and 35 were randomized to avoid antiplatelet treatment. No patients were excluded from analyses. The median age was 75 (Q1–Q3, 66–80) years, and 43 (75%) had previous ischemic stroke or transient ischemic attack. Five patients in the start antiplatelet treatment group (15% [95% CI, 6%–31%]), and 1 in the avoid group (3% [95% CI, 0%–18%]) experienced recurrent ICH, while 3 (9% [95% CI, 3%–24%]) and 7 (20% [95% CI, 10%–37%]), respectively, experienced a major ischemic event. A total of 88 serious adverse events and no suspected unexpected serious adverse reactions were registered. CONCLUSIONS: There were numerically more recurrent ICHs and fewer ischemic events in patients starting antiplatelet treatment after ICH compared with those avoiding antiplatelet treatment. The slow recruitment might be due to clinicians being certain of the best treatment strategy or patients being too frail to participate. STATICH will contribute to a planned collaborative individual patient-data meta-analysis to resolve this dilemma.
- 18 June 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (8) , 2287-2294
Study of Antithrombotic Treatment After Intracerebral Hemorrhage-Antiplatelets: A Randomized Trial
BACKGROUND: Patients surviving spontaneous intracerebral hemorrhage (ICH) who have indications for antithrombotic treatment face increased risks of both hemorrhagic and ischemic events. The aim of STATICH (Study of Antithrombotic Treatment After Intracerebral Haemorrhage) was to assess the safety and efficacy of long-term antithrombotic treatment after ICH. METHODS: STATICH Antiplatelets (EudraCT 2014-002636-13; Unique identifier: NCT03186729) was a randomized, multicenter, open, blinded end point parallel-group trial, including adults with an indication for antiplatelet treatment to either start or avoid antiplatelet treatment. The target sample size was 500 participants. Patients were allocated 1:1 by a Web-based randomization system and followed for a minimum of 2 years. Outcome assessments were done by personnel blinded to treatment. Participants were not blinded. The primary safety outcome was recurrent symptomatic ICH. RESULTS: The trial was stopped early due to slow recruitment. Sixty-nine patients were included between August 2018 and December 2022: 34 were randomized to start antiplatelet treatment, and 35 were randomized to avoid antiplatelet treatment. No patients were excluded from analyses. The median age was 75 (Q1–Q3, 66–80) years, and 43 (75%) had previous ischemic stroke or transient ischemic attack. Five patients in the start antiplatelet treatment group (15% [95% CI, 6%–31%]), and 1 in the avoid group (3% [95% CI, 0%–18%]) experienced recurrent ICH, while 3 (9% [95% CI, 3%–24%]) and 7 (20% [95% CI, 10%–37%]), respectively, experienced a major ischemic event. A total of 88 serious adverse events and no suspected unexpected serious adverse reactions were registered. CONCLUSIONS: There were numerically more recurrent ICHs and fewer ischemic events in patients starting antiplatelet treatment after ICH compared with those avoiding antiplatelet treatment. The slow recruitment might be due to clinicians being certain of the best treatment strategy or patients being too frail to participate. STATICH will contribute to a planned collaborative individual patient-data meta-analysis to resolve this dilemma.
- Open Access
- 23 March 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (4)
Cryptogenic stroke in women: impact of insertable cardiac monitoring in the STROKEWISE cohort study
Aims: The clinical value of insertable cardiac monitoring (ICM) for detecting asymptomatic atrial fibrillation (AF) and guiding anticoagulation in patients with cryptogenic stroke remains uncertain. This study aimed to evaluate the association between ICM-detected AF and recurrent stroke, mortality, and major bleeding in women. Methods and results: We consecutively compared women with cryptogenic stroke who received an ICM at Akershus University Hospital (2016–23), with a control group from Haukeland University Hospital with standard non-invasive follow-up. Participants from both hospitals had complete data in the Norwegian Stroke Registry. Primary outcomes were AF detection and recurrent stroke at 1 and 2 years; secondary outcomes included mortality, composite stroke and mortality, ischaemic cardiovascular events, oral anticoagulation initiation, and major bleeding. Multivariable logistic regression analysis was used for binary outcomes and Cox proportional hazards models for time-to-event outcomes, both adjusted for prespecified vascular risk factors. Among 475 women (mean age 73 ± 12 years; ICM n = 262), AF was detected in 36% in the ICM group vs. 9% in in the control group (OR 6.9, 95% CI 3.7–13.5; P < 0.001). No significant differences were observed in recurrent stroke (HR 1.8, 95% CI 0.78–4.36; P = 0.17), mortality (HR 0.88, 95% CI 0.58–1.58; P = 0.88), or the composite outcome (HR 0.96, 95% CI 0.6–1.5; P = 0.85) with a median follow-up of 42 months (IQR 15–66). However, fixed-time analyses showed significantly lower 2-year mortality with ICM (OR 0.40, 95% CI 0.16–0.94; P = 0.036) and fewer bleeding events (OR 0.19, 95% CI 0.06–0.52; P = 0.002). Age and troponin T were consistent independent predictors of adverse outcomes. Conclusion: ICM increased AF detection and enabled safe anticoagulation in women with acute cryptogenic stroke. Although stroke recurrence did not differ significantly, signals of lower mortality and major bleeding support prolonged monitoring to optimize secondary prevention. ClinicalTrials.gov Identifier: NCT07194811, https://clinicaltrials.gov/study/NCT07194811
- 23 March 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (4)
Open AccessCryptogenic stroke in women: impact of insertable cardiac monitoring in the STROKEWISE cohort study
Aims: The clinical value of insertable cardiac monitoring (ICM) for detecting asymptomatic atrial fibrillation (AF) and guiding anticoagulation in patients with cryptogenic stroke remains uncertain. This study aimed to evaluate the association between ICM-detected AF and recurrent stroke, mortality, and major bleeding in women. Methods and results: We consecutively compared women with cryptogenic stroke who received an ICM at Akershus University Hospital (2016–23), with a control group from Haukeland University Hospital with standard non-invasive follow-up. Participants from both hospitals had complete data in the Norwegian Stroke Registry. Primary outcomes were AF detection and recurrent stroke at 1 and 2 years; secondary outcomes included mortality, composite stroke and mortality, ischaemic cardiovascular events, oral anticoagulation initiation, and major bleeding. Multivariable logistic regression analysis was used for binary outcomes and Cox proportional hazards models for time-to-event outcomes, both adjusted for prespecified vascular risk factors. Among 475 women (mean age 73 ± 12 years; ICM n = 262), AF was detected in 36% in the ICM group vs. 9% in in the control group (OR 6.9, 95% CI 3.7–13.5; P < 0.001). No significant differences were observed in recurrent stroke (HR 1.8, 95% CI 0.78–4.36; P = 0.17), mortality (HR 0.88, 95% CI 0.58–1.58; P = 0.88), or the composite outcome (HR 0.96, 95% CI 0.6–1.5; P = 0.85) with a median follow-up of 42 months (IQR 15–66). However, fixed-time analyses showed significantly lower 2-year mortality with ICM (OR 0.40, 95% CI 0.16–0.94; P = 0.036) and fewer bleeding events (OR 0.19, 95% CI 0.06–0.52; P = 0.002). Age and troponin T were consistent independent predictors of adverse outcomes. Conclusion: ICM increased AF detection and enabled safe anticoagulation in women with acute cryptogenic stroke. Although stroke recurrence did not differ significantly, signals of lower mortality and major bleeding support prolonged monitoring to optimize secondary prevention. ClinicalTrials.gov Identifier: NCT07194811, https://clinicaltrials.gov/study/NCT07194811
- Open Access
- 6 December 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (1) , 108518
Association between blood pressure and outcome in patients with acute ischemic stroke treated with alteplase
- 6 December 2025
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (1) , 108518
Open AccessAssociation between blood pressure and outcome in patients with acute ischemic stroke treated with alteplase
- Open Access
- 1 December 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 10 (4) , 1402-1412
Impact of white matter lesions on associations between prehospital blood pressure and outcomes in spontaneous intracerebral hemorrhage
Introduction: There are concerns about the safety of intensive blood pressure (BP) lowering in intracerebral hemorrhage (ICH) patients with white matter lesions (WML). We explored the impact of WML on associations between i) prehospital BP, and ii) BP change, and outcomes in acute, spontaneous ICH. Patients and methods: This retrospective study included consecutive patients with acute spontaneous ICH, admitted 2011–2020. WML on non-contrast computed tomography were categorized as none-to-mild (0–1) or moderate-to-severe (2–3) on the Fazekas scale. The first systolic BP (SBP) and mean arterial pressure (MAP) from the ambulance and admission, and absolute BP change between these time points, were collected. The outcomes were in-hospital mortality, mortality at 180 days, modified Rankin Scale (mRS) scores at 3 months, and hematoma expansion. Results: Of 548 patients, 260 (47%) had moderate-to-severe WML. Compared to patients with none-to-mild WML, these patients had a stronger association between higher prehospital MAP and in-hospital mortality (p interaction 0.017). WML did not modify associations between prehospital BP and other outcomes. WML modified associations between MAP change and in-hospital mortality (p interaction 0.049), MAP change and mRS score 3–6 at 3 months (p interaction 0.032), and SBP change and mRS score 3–6 at 3 months (p interaction 0.022). These outcomes were poorer with greater BP decrease in patients with moderate-to-severe compared to none-to-mild WML. Discussion and conclusion: In acute ICH, WML modified the influence of prehospital BP and BP change on clinical outcomes, with a trend toward worse outcomes associated with higher prehospital BP and greater spontaneous BP decrease.
- 1 December 2025
- Published by Oxford University Press (OUP) in European Stroke Journal
- Vol. 10 (4) , 1402-1412
Open AccessImpact of white matter lesions on associations between prehospital blood pressure and outcomes in spontaneous intracerebral hemorrhage
Introduction: There are concerns about the safety of intensive blood pressure (BP) lowering in intracerebral hemorrhage (ICH) patients with white matter lesions (WML). We explored the impact of WML on associations between i) prehospital BP, and ii) BP change, and outcomes in acute, spontaneous ICH. Patients and methods: This retrospective study included consecutive patients with acute spontaneous ICH, admitted 2011–2020. WML on non-contrast computed tomography were categorized as none-to-mild (0–1) or moderate-to-severe (2–3) on the Fazekas scale. The first systolic BP (SBP) and mean arterial pressure (MAP) from the ambulance and admission, and absolute BP change between these time points, were collected. The outcomes were in-hospital mortality, mortality at 180 days, modified Rankin Scale (mRS) scores at 3 months, and hematoma expansion. Results: Of 548 patients, 260 (47%) had moderate-to-severe WML. Compared to patients with none-to-mild WML, these patients had a stronger association between higher prehospital MAP and in-hospital mortality (p interaction 0.017). WML did not modify associations between prehospital BP and other outcomes. WML modified associations between MAP change and in-hospital mortality (p interaction 0.049), MAP change and mRS score 3–6 at 3 months (p interaction 0.032), and SBP change and mRS score 3–6 at 3 months (p interaction 0.022). These outcomes were poorer with greater BP decrease in patients with moderate-to-severe compared to none-to-mild WML. Discussion and conclusion: In acute ICH, WML modified the influence of prehospital BP and BP change on clinical outcomes, with a trend toward worse outcomes associated with higher prehospital BP and greater spontaneous BP decrease.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 2895-2903
Device-Detected Atrial Fibrillation in Patients With and Without Cryptogenic Ischemia: The ANTARCTICA Pooled Analysis
BACKGROUND: Insertable cardiac monitoring (ICM) detects atrial fibrillation (AF) in substantial proportions of cryptogenic stroke, noncryptogenic ischemic stroke without known AF, and nonstroke patients who are at risk of underlying AF. Given differences in patient characteristics across studies, there may be differences in AF detection rates on ICM across these subgroups that have not been identified. We investigate whether AF detection rates on ICM are higher in cryptogenic stroke or transient ischemic attack (C-IS/TIA) patients compared with individuals with noncryptogenic stroke or without stroke, when accounting for differences in study populations. METHODS: This is an individual-participant data meta-analysis of prospective studies and randomized controlled trials of ICM in C-IS/TIA, noncryptogenic ischemic stroke, and nonstroke patients. Multilevel multivariable logistic regression models were used to test whether C-IS/TIA is associated with increased AF detection relative to other categories. We performed multiple imputation to derive values for variables with P =0.009), indicating that 47% of AF detected in C-IS/TIA is pathogenic. Limiting the comparator group to ischemic stroke or history of stroke yielded similar results (adjusted odds ratio, 2.83 [95% CI, 1.47–5.44]; P =0.002). Days to AF detection were significantly shorter in C-IS/TIA patients (median 65 versus 169; P <0.001). CONCLUSIONS: In this individual-participant data meta-analysis of patients undergoing ICM, AF detection was higher in C-IS/TIA patients, with shorter time to AF detection compared with noncryptogenic/nonstroke individuals. These findings suggest that some of the AF detected in patients with C-IS/TIA may be pathogenic.
- 1 October 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (10) , 2895-2903
Device-Detected Atrial Fibrillation in Patients With and Without Cryptogenic Ischemia: The ANTARCTICA Pooled Analysis
BACKGROUND: Insertable cardiac monitoring (ICM) detects atrial fibrillation (AF) in substantial proportions of cryptogenic stroke, noncryptogenic ischemic stroke without known AF, and nonstroke patients who are at risk of underlying AF. Given differences in patient characteristics across studies, there may be differences in AF detection rates on ICM across these subgroups that have not been identified. We investigate whether AF detection rates on ICM are higher in cryptogenic stroke or transient ischemic attack (C-IS/TIA) patients compared with individuals with noncryptogenic stroke or without stroke, when accounting for differences in study populations. METHODS: This is an individual-participant data meta-analysis of prospective studies and randomized controlled trials of ICM in C-IS/TIA, noncryptogenic ischemic stroke, and nonstroke patients. Multilevel multivariable logistic regression models were used to test whether C-IS/TIA is associated with increased AF detection relative to other categories. We performed multiple imputation to derive values for variables with P =0.009), indicating that 47% of AF detected in C-IS/TIA is pathogenic. Limiting the comparator group to ischemic stroke or history of stroke yielded similar results (adjusted odds ratio, 2.83 [95% CI, 1.47–5.44]; P =0.002). Days to AF detection were significantly shorter in C-IS/TIA patients (median 65 versus 169; P <0.001). CONCLUSIONS: In this individual-participant data meta-analysis of patients undergoing ICM, AF detection was higher in C-IS/TIA patients, with shorter time to AF detection compared with noncryptogenic/nonstroke individuals. These findings suggest that some of the AF detected in patients with C-IS/TIA may be pathogenic.
- Open Access
- 18 February 2025
- Published by Medical Journals Sweden AB in Journal of Rehabilitation Medicine
- Vol. 57, jrm42443
Impact of a stroke care pathway on self-perceived health 3 months after stroke
Background: A national stroke care pathway aiming at reducing time delays in stroke care was implemented in Norway in 2018. This study aimed to investigate the impact of goal attainment in the pre- and intrahospital care pathway on self-perceived health 3 months after stroke. Methods: Data from the Norwegian Stroke Register (NSR) from 2019 were used. Patients were classified into attainment or non-attainment groups, depending on goal achievement of the SCP. Linear regression analyses were used to assess a possible association between goal attainment and self-perceived health evaluated by EQ-5D-5L and EQ-VAS at 3 months post-stroke. Results: Among 4,133 included patients, 908 (22%) were included in the attainment group. We found no effect of goal attainment upon mean EQ-5D-5L. However, when adjusting for stroke severity, attaining the SCP was significantly associated with self-perceived health. Conclusion: In this study, with a cohort of patients with mild to moderate strokes, we found no association between attaining goals of the stroke care pathway and self-perceived health. However, stroke severity might have acted as a suppressor variable underscoring the importance of stroke severity for self-perceived health.
- 18 February 2025
- Published by Medical Journals Sweden AB in Journal of Rehabilitation Medicine
- Vol. 57, jrm42443
Open AccessImpact of a stroke care pathway on self-perceived health 3 months after stroke
Background: A national stroke care pathway aiming at reducing time delays in stroke care was implemented in Norway in 2018. This study aimed to investigate the impact of goal attainment in the pre- and intrahospital care pathway on self-perceived health 3 months after stroke. Methods: Data from the Norwegian Stroke Register (NSR) from 2019 were used. Patients were classified into attainment or non-attainment groups, depending on goal achievement of the SCP. Linear regression analyses were used to assess a possible association between goal attainment and self-perceived health evaluated by EQ-5D-5L and EQ-VAS at 3 months post-stroke. Results: Among 4,133 included patients, 908 (22%) were included in the attainment group. We found no effect of goal attainment upon mean EQ-5D-5L. However, when adjusting for stroke severity, attaining the SCP was significantly associated with self-perceived health. Conclusion: In this study, with a cohort of patients with mild to moderate strokes, we found no association between attaining goals of the stroke care pathway and self-perceived health. However, stroke severity might have acted as a suppressor variable underscoring the importance of stroke severity for self-perceived health.
- Open Access
- 22 August 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002805
Systolic blood pressure at age 40 and 30-year stroke risk in men and women
Background American and European guidelines define hypertension differently and are sex agnostic. Our aim was to assess the impact of different hypertension thresholds at the age of 40 on 30-year stroke risk and to examine sex differences. Methods We included 2608 stroke-free individuals from the Akershus Cardiac Examination 1950 Study, a Norwegian regional study conducted in 2012–2015 of the 1950 birth cohort, who had previously participated in the Age 40 Program, a nationwide health examination study conducted in 1990–1993. We categorised participants by systolic blood pressure (SBP) at age 40 (Results The mean age was 40.1±0.3 years (50.4% women) and mean SBP was 128.3±13.5 mm Hg (mean±SD). Stroke occurred in 115 (4.4%) individuals (32 (28%) women and 83 (72%) men) during 29.4±2.9 years of follow-up. SBP between 130 and 139 mm Hg was not associated with stroke (adjusted HR 1.71, 95% CI 0.87 to 3.36) while SBP ≥140 mm Hg was associated with increased stroke risk (adjusted HR 3.11, 95% CI 1.62 to 6.00). The adjusted HR of stroke was 4.32 (95% CI 1.66 to 11.26) for women and 2.66 (95% CI 1.03 to 6.89) for men, with non-significant sex interactions. Conclusions SBP ≥140 mm Hg was significantly associated with 30-year stroke risk in both sexes. A small subgroup of women had SBP ≥140 mm Hg and systolic hypertension was a strong risk factor for stroke in these women. Trial registration number NCT01555411.
- 22 August 2024
- Published by BMJ in Open Heart
- Vol. 11 (2) , e002805
Open AccessSystolic blood pressure at age 40 and 30-year stroke risk in men and women
Background American and European guidelines define hypertension differently and are sex agnostic. Our aim was to assess the impact of different hypertension thresholds at the age of 40 on 30-year stroke risk and to examine sex differences. Methods We included 2608 stroke-free individuals from the Akershus Cardiac Examination 1950 Study, a Norwegian regional study conducted in 2012–2015 of the 1950 birth cohort, who had previously participated in the Age 40 Program, a nationwide health examination study conducted in 1990–1993. We categorised participants by systolic blood pressure (SBP) at age 40 (Results The mean age was 40.1±0.3 years (50.4% women) and mean SBP was 128.3±13.5 mm Hg (mean±SD). Stroke occurred in 115 (4.4%) individuals (32 (28%) women and 83 (72%) men) during 29.4±2.9 years of follow-up. SBP between 130 and 139 mm Hg was not associated with stroke (adjusted HR 1.71, 95% CI 0.87 to 3.36) while SBP ≥140 mm Hg was associated with increased stroke risk (adjusted HR 3.11, 95% CI 1.62 to 6.00). The adjusted HR of stroke was 4.32 (95% CI 1.66 to 11.26) for women and 2.66 (95% CI 1.03 to 6.89) for men, with non-significant sex interactions. Conclusions SBP ≥140 mm Hg was significantly associated with 30-year stroke risk in both sexes. A small subgroup of women had SBP ≥140 mm Hg and systolic hypertension was a strong risk factor for stroke in these women. Trial registration number NCT01555411.
- Open Access
- 8 February 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (6) , 640-651
Intracerebral haemorrhage in patients taking different types of oral anticoagulants: a pooled individual patient data analysis from two national stroke registries
Background We investigated outcomes in patients with intracerebral haemorrhage (ICH) according to prior anticoagulation treatment with Vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs) or no anticoagulation. Methods This is an individual patient data study combining two prospective national stroke registries from Switzerland and Norway (2013–2019). We included all consecutive patients with ICH from both registries. The main outcomes were favourable functional outcome (modified Rankin Scale 0–2) and mortality at 3 months. Results Among 11 349 patients with ICH (mean age 73.6 years; 47.6% women), 1491 (13.1%) were taking VKAs and 1205 (10.6%) DOACs (95.2% factor Xa inhibitors). The median percentage of patients on prior anticoagulation was 23.7 (IQR 22.6–25.1) with VKAs decreasing (from 18.3% to 7.6%) and DOACs increasing (from 3.0% to 18.0%) over time. Prior VKA therapy (n=209 (22.3%); adjusted ORs (aOR), 0.64; 95% CI, 0.49 to 0.84) and prior DOAC therapy (n=184 (25.7%); aOR, 0.64; 95% CI, 0.47 to 0.87) were independently associated with lower odds of favourable outcome compared with patients without anticoagulation (n=2037 (38.8%)). Prior VKA therapy (n=720 (49.4%); aOR, 1.71; 95% CI, 1.41 to 2.08) and prior DOAC therapy (n=460 (39.7%); aOR, 1.28; 95% CI, 1.02 to 1.60) were independently associated with higher odds of mortality compared with patients without anticoagulation (n=2512 (30.2%)). Conclusions The spectrum of anticoagulation-associated ICH changed over time. Compared with patients without prior anticoagulation, prior VKA treatment and prior DOAC treatment were independently associated with lower odds of favourable outcome and higher odds of mortality at 3 months. Specific reversal agents unavailable during the study period might improve outcomes of DOAC-associated ICH in the future.
- 8 February 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (6) , 640-651
Open AccessIntracerebral haemorrhage in patients taking different types of oral anticoagulants: a pooled individual patient data analysis from two national stroke registries
Background We investigated outcomes in patients with intracerebral haemorrhage (ICH) according to prior anticoagulation treatment with Vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs) or no anticoagulation. Methods This is an individual patient data study combining two prospective national stroke registries from Switzerland and Norway (2013–2019). We included all consecutive patients with ICH from both registries. The main outcomes were favourable functional outcome (modified Rankin Scale 0–2) and mortality at 3 months. Results Among 11 349 patients with ICH (mean age 73.6 years; 47.6% women), 1491 (13.1%) were taking VKAs and 1205 (10.6%) DOACs (95.2% factor Xa inhibitors). The median percentage of patients on prior anticoagulation was 23.7 (IQR 22.6–25.1) with VKAs decreasing (from 18.3% to 7.6%) and DOACs increasing (from 3.0% to 18.0%) over time. Prior VKA therapy (n=209 (22.3%); adjusted ORs (aOR), 0.64; 95% CI, 0.49 to 0.84) and prior DOAC therapy (n=184 (25.7%); aOR, 0.64; 95% CI, 0.47 to 0.87) were independently associated with lower odds of favourable outcome compared with patients without anticoagulation (n=2037 (38.8%)). Prior VKA therapy (n=720 (49.4%); aOR, 1.71; 95% CI, 1.41 to 2.08) and prior DOAC therapy (n=460 (39.7%); aOR, 1.28; 95% CI, 1.02 to 1.60) were independently associated with higher odds of mortality compared with patients without anticoagulation (n=2512 (30.2%)). Conclusions The spectrum of anticoagulation-associated ICH changed over time. Compared with patients without prior anticoagulation, prior VKA treatment and prior DOAC treatment were independently associated with lower odds of favourable outcome and higher odds of mortality at 3 months. Specific reversal agents unavailable during the study period might improve outcomes of DOAC-associated ICH in the future.
- Top Cited PapersOpen Access
- 5 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (17) , e030739
Carotid Plaque Score for Stroke and Cardiovascular Risk Prediction in a Middle‐Aged Cohort From the General Population
Background: We aimed to explore the predictive value of the carotid plaque score, compared with the Systematic Coronary Risk Evaluation 2 (SCORE2) risk prediction algorithm, on incident ischemic stroke and major adverse cardiovascular events and establish a prognostic cutoff of the carotid plaque score. Methods and Results: In the prospective ACE 1950 (Akershus Cardiac Examination 1950 study), carotid plaque score was calculated with ultrasonography at inclusion in 2012 to 2015. The largest plaque diameter in each extracranial segment of the carotid artery on both sides was scored from 0 to 3 points. The sum of points in all segments provided the carotid plaque score. The cohort was followed up by linkage to national registries for incident ischemic stroke and major adverse cardiovascular events (nonfatal ischemic stroke, nonfatal myocardial infarction, and cardiovascular death) throughout 2020. Carotid plaque score was available in 3650 (98.5%) participants, with mean±SD age of 63.9±0.64 years at inclusion. Only 462 (12.7%) participants were free of plaque, and and 970 (26.6%) had a carotid plaque score of >3. Carotid plaque score predicted ischemic stroke (hazard ratio [HR], 1.25 [95% CI, 1.15–1.36]) and major adverse cardiovascular events (HR, 1.21 [95% CI, 1.14–1.27]) after adjustment for SCORE2 and provided strong incremental prognostic information to SCORE2. The best cutoff value of carotid plaque score for ischemic stroke was >3, with positive predictive value of 2.5% and negative predictive value of 99.3%. Conclusions: The carotid plaque score is a strong predictor of ischemic stroke and major adverse cardiovascular events, and it provides incremental prognostic information to SCORE2 for risk prediction. A cutoff score of >3 seems to be suitable to discriminate high‐risk subjects. Registration Information: clinicaltrials.gov. Identifier: NCT01555411.
- 5 September 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (17) , e030739
Top Cited PapersOpen AccessCarotid Plaque Score for Stroke and Cardiovascular Risk Prediction in a Middle‐Aged Cohort From the General Population
Background: We aimed to explore the predictive value of the carotid plaque score, compared with the Systematic Coronary Risk Evaluation 2 (SCORE2) risk prediction algorithm, on incident ischemic stroke and major adverse cardiovascular events and establish a prognostic cutoff of the carotid plaque score. Methods and Results: In the prospective ACE 1950 (Akershus Cardiac Examination 1950 study), carotid plaque score was calculated with ultrasonography at inclusion in 2012 to 2015. The largest plaque diameter in each extracranial segment of the carotid artery on both sides was scored from 0 to 3 points. The sum of points in all segments provided the carotid plaque score. The cohort was followed up by linkage to national registries for incident ischemic stroke and major adverse cardiovascular events (nonfatal ischemic stroke, nonfatal myocardial infarction, and cardiovascular death) throughout 2020. Carotid plaque score was available in 3650 (98.5%) participants, with mean±SD age of 63.9±0.64 years at inclusion. Only 462 (12.7%) participants were free of plaque, and and 970 (26.6%) had a carotid plaque score of >3. Carotid plaque score predicted ischemic stroke (hazard ratio [HR], 1.25 [95% CI, 1.15–1.36]) and major adverse cardiovascular events (HR, 1.21 [95% CI, 1.14–1.27]) after adjustment for SCORE2 and provided strong incremental prognostic information to SCORE2. The best cutoff value of carotid plaque score for ischemic stroke was >3, with positive predictive value of 2.5% and negative predictive value of 99.3%. Conclusions: The carotid plaque score is a strong predictor of ischemic stroke and major adverse cardiovascular events, and it provides incremental prognostic information to SCORE2 for risk prediction. A cutoff score of >3 seems to be suitable to discriminate high‐risk subjects. Registration Information: clinicaltrials.gov. Identifier: NCT01555411.
- Open Access
How attaining the goals of a stroke care pathway is related to functional outcome after stroke. A nationwide study
Background and purpose In 2018 a stroke care pathway (SCP) was introduced in Norway. The goal of the pathway was to improve acute stroke care by reducing time-delay. We aimed to evaluate if achieving the target times of the SCP was associated with a better functional outcome at 3 months post-stroke and to identify characteristics of patients attaining the goals. Methods We performed a register-based study with data from the Norwegian stroke register (NSR). Patients registered with acute stroke in 2019 were included. Functional outcome at 3 months in the patients with “achievement” was compared to patients with “non-achievement”. Achievement was defined as attaining three important goals in the SCP; 1) time from symptom onset to contact with the emergency medical service, 2) time from symptom onset to arrival in hospital, 3) time from arrival in hospital to admission to a stroke unit. Additionally, we evaluated time from arrival in hospital to treatment with intravenous thrombolysis. Modified Rankin Scale (mRS) was used to measure functional outcome at 3 months post-stroke and functional independence was defined as mRS 0-2. Characteristics of the “achievers” were analysed by univariate and multivariate logistic regression analyses. Results In total 2818 patients were included, 460 (16%) were in the achievement group. The mean (SD) age was 72.5 (12.6) years and 1201 (43%) were women. The probability of being independent at 3 months post-stroke was significantly higher in the achievement group versus the non-achievement group (OR 1.36, 95% CI 1.04-1.79, p=0.026). The “achievers” were significantly younger, less likely to be living alone, less likely to have diabetes, more often had an ischemic stroke and were admitted with more severe strokes than the “non-achievers”. Conclusion Goal achievement in the SCP was significantly associated with independence 3 months post-stroke.
Open AccessHow attaining the goals of a stroke care pathway is related to functional outcome after stroke. A nationwide study
Background and purpose In 2018 a stroke care pathway (SCP) was introduced in Norway. The goal of the pathway was to improve acute stroke care by reducing time-delay. We aimed to evaluate if achieving the target times of the SCP was associated with a better functional outcome at 3 months post-stroke and to identify characteristics of patients attaining the goals. Methods We performed a register-based study with data from the Norwegian stroke register (NSR). Patients registered with acute stroke in 2019 were included. Functional outcome at 3 months in the patients with “achievement” was compared to patients with “non-achievement”. Achievement was defined as attaining three important goals in the SCP; 1) time from symptom onset to contact with the emergency medical service, 2) time from symptom onset to arrival in hospital, 3) time from arrival in hospital to admission to a stroke unit. Additionally, we evaluated time from arrival in hospital to treatment with intravenous thrombolysis. Modified Rankin Scale (mRS) was used to measure functional outcome at 3 months post-stroke and functional independence was defined as mRS 0-2. Characteristics of the “achievers” were analysed by univariate and multivariate logistic regression analyses. Results In total 2818 patients were included, 460 (16%) were in the achievement group. The mean (SD) age was 72.5 (12.6) years and 1201 (43%) were women. The probability of being independent at 3 months post-stroke was significantly higher in the achievement group versus the non-achievement group (OR 1.36, 95% CI 1.04-1.79, p=0.026). The “achievers” were significantly younger, less likely to be living alone, less likely to have diabetes, more often had an ischemic stroke and were admitted with more severe strokes than the “non-achievers”. Conclusion Goal achievement in the SCP was significantly associated with independence 3 months post-stroke.